Nutrition in Critical Illness — Part 2: Enteral Nutrition

1. Early Enteral Nutrition — Timing and Rationale

1.1 Recommendation

Enteral nutrition (EN) should be initiated within 24 to 48 hours of ICU admission in critically ill patients who are unable to maintain volitional oral intake, provided they are hemodynamically stable (i.e., mean arterial pressure is at target with stable or decreasing vasopressor doses, and no active titration of fluid resuscitation).^{1 2 3}

1.2 Physiological Rationale for Early EN

Early enteral feeding exerts benefits beyond simple nutrient delivery:

• Maintenance of gut mucosal integrity: The intestinal epithelium turns over every 3-5 days and depends on intraluminal nutrient stimulation. Fasting leads to villous atrophy, increased mucosal permeability, and bacterial translocation.
• Preservation of gut-associated lymphoid tissue (GALT): Approximately 70% of immune tissue resides in the gut. EN stimulates IgA secretion and maintains GALT function.
• Modulation of the stress response: Early EN attenuates the systemic inflammatory response and reduces the magnitude of the hypermetabolic state.
• Reduction in infectious complications: Multiple meta-analyses demonstrate that early EN (within 24-48 hours) compared to delayed EN (after 48 hours) is associated with reduced infectious complications (relative risk 0.74; 95% CI 0.58-0.93) and reduced ICU length of stay, though effects on mortality have been inconsistent.⁴

1.3 Prerequisites for Initiating EN

1.4 Absolute Contraindications to EN

• Mechanical bowel obstruction (non-functional GI tract distal to the feeding site)
• Active GI hemorrhage requiring intervention (once controlled, EN can be initiated)
• Bowel ischemia (mesenteric ischemia, confirmed or strongly suspected)
• High-output GI fistula (unless feeding access is distal to the fistula)
• Abdominal compartment syndrome with intra-abdominal pressure > 20 mmHg and new organ dysfunction
• Intestinal discontinuity (not yet surgically reconstructed)

1.5 Relative Contraindications / Situations Requiring Caution

• High-dose vasopressor therapy (norepinephrine > 0.14 mcg/kg/min or equivalent) — weigh risks vs benefits
• Severe gastric or intestinal ileus
• Recent bowel anastomosis (though early post-operative EN is generally safe in most situations)
• Hemodynamically significant GI bleeding (once stabilized, EN may be cautiously restarted)
• Short bowel syndrome with high-volume output

2. Route of Enteral Access

2.1 Gastric Feeding (Standard First-Line)

Gastric feeding via nasogastric (NG) or orogastric (OG) tube is the recommended initial route for EN in most critically ill patients due to ease of insertion, rapid access, and the physiological advantages of gastric feeding (stimulation of gastric acid secretion, bile flow, and pancreatic function).^{1 2}

Tube selection:

• Standard bore: 12-16 French (Fr) — suitable for most commercial formulas
• Small bore: 8-12 Fr — may be more comfortable for patients but more prone to clogging
• OG tubes are preferred in patients with severe coagulopathy, basilar skull fracture, or significant facial trauma (where nasogastric insertion is contraindicated)

2.2 Post-Pyloric (Small Bowel) Feeding

Post-pyloric feeding (nasoduodenal or nasojejunal) is indicated in specific clinical situations where gastric feeding has failed or is considered high risk.^{1 2}

Indications for Post-Pyloric Feeding

Methods of Post-Pyloric Tube Placement

2.3 Percutaneous Enteral Access (Long-Term)

For patients expected to require EN for > 4-6 weeks, percutaneous access should be considered:

• Percutaneous endoscopic gastrostomy (PEG): Standard for long-term gastric feeding. Placement timing varies; typically considered after 2-4 weeks of nasoenteric feeding when prolonged need is anticipated.
• Percutaneous endoscopic gastrojejunostomy (PEG-J): For patients requiring long-term post-pyloric feeding.
• Direct percutaneous endoscopic jejunostomy (DPEJ): Alternative for patients with contraindications to PEG (prior gastric surgery, ascites, interposed colon).
• Surgical gastrostomy or jejunostomy: Placed at the time of open or laparoscopic abdominal surgery.

3. EN Initiation and Advancement Protocol

3.1 Trophic (Trickle) Feeding Phase

Rationale: Low-volume EN in the first 24-48 hours provides gut mucosal benefits while minimizing the risk of GI intolerance during the acute ebb phase of critical illness.⁵

3.2 Advancement to Goal Rate

After the trophic phase (or immediately in patients not at high risk for intolerance), EN should be advanced toward the goal rate in a systematic fashion:^{1 2}

Sample Goal Rate Calculation

Example: Patient with target of 1,800 kcal/day using 1.2 kcal/mL formula

Goal rate = 1,800 / (1.2 x 24) = 1,800 / 28.8 = 62.5 mL/hr (round to 63 mL/hr)

3.3 Volume-Based Feeding Protocol (Alternative Approach)

Volume-based (or rate-based catch-up) protocols specify a total daily volume rather than an hourly rate, allowing nurses to increase the hourly rate to compensate for time lost to holds (procedures, high GRV, transport). This approach has been shown to improve caloric delivery compared to traditional rate-based protocols.⁶

Protocol:

1. Calculate daily volume target: Goal rate x 24 hours = daily volume (e.g., 63 mL/hr x 24 = 1,512 mL/day)
2. If EN is held for any reason, increase the rate for the remainder of the 24-hour period to deliver the full daily volume
3. Maximum allowable rate: typically capped at 150% of goal rate (e.g., if goal = 63, max = 95 mL/hr)
4. If less than 6 hours remain in the 24-hour period, do not attempt to catch up

4. Enteral Formula Selection

4.1 Standard Polymeric Formulas (First-Line)

Standard polymeric formulas are appropriate for the majority of critically ill patients and should be the default selection. These contain intact proteins, complex carbohydrates, and long-chain triglycerides.^{1 2}

4.2 High-Protein Formulas

Preferred for most ICU patients to help meet protein targets of 1.2-2.0 g/kg/day without excessive caloric delivery. High-protein formulas typically provide >= 25% of calories from protein (protein:calorie ratio >= 1:100 or higher).²

4.3 Calorie-Dense Formulas (1.5-2.0 kcal/mL)

Indicated for patients requiring fluid restriction (heart failure, SIADH, renal failure, ARDS with conservative fluid strategy). Trade-offs include higher osmolality and potentially increased risk of diarrhea.

4.4 Semi-Elemental and Elemental Formulas

These contain hydrolyzed or pre-digested proteins (peptides or free amino acids) and medium-chain triglycerides (MCTs) for easier absorption.

Indications:

• Severe malabsorption
• Short bowel syndrome
• Chronic diarrhea unresponsive to standard formula adjustments
• Severe pancreatitis (some evidence, though standard polymeric is acceptable in most cases)
• GI fistula (may reduce fistula output)
• Chylothorax (MCT-based formulas reduce lymphatic flow)

Note: Routine use of semi-elemental or elemental formulas is not recommended in the general ICU population, as they offer no proven benefit over standard polymeric formulas and are significantly more expensive.¹

4.5 Disease-Specific Formulas

4.6 Fiber in Enteral Formulas

Contraindications to fiber-containing formulas: hemodynamic instability, high-dose vasopressors, suspected bowel ischemia, bowel obstruction, post-pyloric feeding in some cases.^{1 2}

5. Gastric Residual Volume (GRV) Management

5.1 Current Evidence and Recommendations

The practice of routinely measuring gastric residual volumes has been challenged by recent evidence. The landmark NUTRIREA-2 study and other trials have demonstrated that GRV monitoring does not reliably predict aspiration or pneumonia and may lead to unnecessary interruptions in EN delivery.^{7 8}

Position of Major Societies

5.2 When GRV Monitoring May Still Be Warranted

Despite the trend away from routine GRV monitoring, there are clinical situations where it remains prudent:

• First 48 hours of EN initiation (to identify patients with significant gastroparesis early)
• Patients at high risk for aspiration (altered mental status, supine positioning, history of aspiration)
• Patients with clinical signs of intolerance (abdominal distension, vomiting, regurgitation)
• During vasopressor therapy (particularly when escalating doses)

5.3 GRV Threshold Protocol (When Monitored)

Important: Always return the gastric aspirate to the patient (unless it is grossly bloody or the volume is extreme) to prevent electrolyte and fluid losses.¹

6. Prokinetic Agents

6.1 Overview

Prokinetic agents are recommended when EN intolerance persists despite optimization of other factors (head-of-bed elevation, avoidance of constipation, glycemic control, minimization of opioids).^{1 2 3}

6.2 Metoclopramide

6.3 Erythromycin

6.4 Combination Therapy

When a single prokinetic agent is ineffective, combination therapy with metoclopramide + erythromycin may be used, as they act through different mechanisms (dopamine antagonism vs motilin agonism). Evidence for combination therapy is limited but suggests additive benefit.¹

Recommended approach:

1. Start with metoclopramide 10 mg IV every 6 hours
2. If GRV remains elevated after 24-48 hours, ADD erythromycin 250 mg IV every 12 hours
3. Reassess after 48-72 hours of combination therapy
4. If still intolerant, pursue post-pyloric access
5. Discontinue prokinetics once EN tolerance is established (typically within 5-7 days)

6.5 Other Prokinetic Considerations

• Naloxone (enteral): 4-8 mg via feeding tube every 6 hours — may improve GI motility in patients receiving opioids; acts locally in the gut lumen. Limited evidence in the ICU.
• Methylnaltrexone (subcutaneous): 8-12 mg SC every other day — peripheral mu-opioid receptor antagonist for opioid-induced constipation; does not cross the blood-brain barrier.

7. EN Complications — Prevention and Management

7.1 Aspiration

Aspiration of gastric contents is the most feared complication of EN, though its incidence is lower than historically believed (< 5% with appropriate preventive measures).^{1 9}

Aspiration Risk Reduction Strategies

7.2 Diarrhea

Diarrhea occurs in 15-40% of enterally fed ICU patients and has multiple potential etiologies beyond EN itself.¹

Diarrhea Assessment — Bristol Stool Scale in the ICU

Common Causes of Diarrhea in the ICU (Beyond EN)

Diarrhea Management Protocol

1. Rule out C. difficile — send stool for C. difficile toxin testing (PCR or toxin EIA)
2. Review medication list — identify and eliminate sorbitol-containing liquid medications, unnecessary antibiotics, and magnesium-containing products
3. Do NOT empirically stop EN — EN is rarely the primary cause of diarrhea in the ICU
4. Formula adjustments (if formula-related diarrhea is suspected):
   • Reduce rate temporarily (by 25-50%) and advance gradually
   • Switch to iso-osmolar formula if currently using hypertonic
   • Consider adding soluble fiber (e.g., 10-15 g/day of partially hydrolyzed guar gum) in hemodynamically stable patients
   • Consider semi-elemental formula if malabsorption is suspected
5. Fecal management system — consider for severe diarrhea to protect skin integrity and enable accurate output measurement
6. Anti-diarrheal agents — use only after ruling out infectious etiology:
   • Loperamide 2-4 mg every 6 hours (avoid in C. difficile infection)
   • Banana flakes (dietary fiber supplement)

7.3 Tube Clogging — Prevention and Treatment

Prevention

• Flush feeding tube with 30 mL of water every 4-6 hours during continuous infusion
• Flush with 30 mL of water before and after each medication administration
• Flush with 30 mL of water before and after each GRV check
• Never mix medications together in the feeding tube
• Use liquid formulations of medications when available
• Crush tablets to a fine powder and dissolve in water before administration (verify that the medication can be crushed — do not crush enteric-coated or sustained-release formulations)

Tube Declogging Protocol

7.4 Refeeding Syndrome

Refeeding syndrome is a potentially life-threatening metabolic complication that occurs when nutrition is reintroduced after a period of starvation or severe malnutrition. It is characterized by dangerous shifts in electrolytes — particularly phosphate — as insulin-driven cellular uptake of phosphate, potassium, magnesium, and water occurs with carbohydrate reintroduction.^{10 11}

Detailed coverage of refeeding syndrome pathophysiology, risk factors, and prevention protocol is provided in Part 3, Section 7.

8. Monitoring EN Tolerance

8.1 Daily Assessment Checklist

9. EN During Prone Positioning

9.1 Feasibility and Safety

Prone positioning is an established therapy for moderate-to-severe ARDS (P/F ratio < 150). Traditionally, EN has been held or reduced during prone sessions due to concerns about aspiration and abdominal intolerance. However, emerging evidence suggests that EN can be safely continued during prone positioning with appropriate precautions.¹²

9.2 Protocol for EN During Prone Positioning

9.3 Evidence Summary

• A multicenter observational study demonstrated that EN during prone positioning was feasible, with similar rates of vomiting and ventilator-associated pneumonia compared to EN during supine positioning.¹²
• Caloric delivery was improved when EN was continued during prone sessions rather than held
• Post-pyloric feeding during prone positioning has been associated with improved tolerance in small studies

10. EN During Vasopressor Therapy

10.1 Overview

The safety of EN during vasopressor therapy is one of the most debated topics in ICU nutrition. Vasopressors cause splanchnic vasoconstriction, and there is theoretical concern that EN increases mesenteric oxygen demand in the setting of compromised blood flow, potentially leading to non-occlusive mesenteric ischemia (NOMI).^{1 2 13}

10.2 Risk of Mesenteric Ischemia

The incidence of clinically significant bowel ischemia attributable to EN during vasopressor therapy is low (estimated at < 1%), but the condition carries high mortality (50-80% when it occurs).¹³

Risk Factors for Mesenteric Ischemia During EN

10.3 Practical Approach to EN During Vasopressor Therapy

10.4 Warning Signs of Mesenteric Ischemia During EN

If any of the following develop, EN should be immediately stopped and mesenteric ischemia should be evaluated:

• Abdominal distension (new or worsening)
• Abdominal tenderness or guarding
• Absent or significantly diminished bowel sounds
• Bloody or melanotic stools / bloody gastric aspirate
• Rising serum lactate without other explanation
• Worsening metabolic acidosis
• Unexplained clinical deterioration
• Pneumatosis intestinalis or portal venous gas on imaging

Evaluation: CT angiography of the abdomen/pelvis; surgical consultation.¹³

11. EN and Procedures — Holding Protocols

11.1 Pre-Procedural EN Holds

11.2 Post-Procedural EN Resumption

• After extubation: Resume EN when the patient passes a swallowing assessment (if transitioning to oral intake) or when post-pyloric/gastric access is re-established
• After surgery: Resume EN as soon as hemodynamically stable, typically within 12-24 hours post-operatively; early post-operative EN is safe and beneficial in most surgical patients
• After bronchoscopy: Resume 1-2 hours after procedure if no complications

12. Summary of Enteral Nutrition Recommendations

References